REGN
Price
$951.19Alerts
Change
-$8.22 (-0.86%)
Updated
Nov 12 closing price
Capitalization
93.11B
77 days until earnings call
Intraday BUY SELL Signals
RPRX
Price
$68.97Alerts
Change
-$1.04 (-1.49%)
Updated
Nov 12 closing price
Capitalization
29.97B
95 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

REGN vs RPRX

REGN vs RPRX Comparison Chart in %
View a ticker or compare two or three
VS
REGN vs. RPRX commentary
Nov 13, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REGN is a Buy and RPRX is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for REGN with price predictions
Nov 12, 2026

REGN in upward trend: 10-day moving average moved above 50-day moving average on October 26, 2026

The 10-day moving average for REGN crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on REGN as a result. In 58 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.

The Moving Average Convergence Divergence (MACD) for REGN just turned positive on October 14, 2026. Looking at past instances where REGN's MACD turned positive, the stock continued to rise in 35 of 49 cases over the following month. The odds of a continued upward trend are 71%.

REGN moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in 203 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

The Aroon Indicator entered an Uptrend today. In 186 of 264 cases where REGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.

Bearish Trend Analysis

The 10-day RSI Indicator for REGN moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 15 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 37%.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.

REGN broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 3 (best 1 - 100 worst), indicating outstanding price growth. REGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 62 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.936) is normal, around the industry mean (3.498). P/E Ratio (21.599) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (1.238) is also within normal values, averaging (9.059). Dividend Yield (0.004) settles around the average of (130.981) among similar stocks. P/S Ratio (5.339) is also within normal values, averaging (440.869).

A.I.Advisor
a Summary for RPRX with price predictions
Nov 12, 2026

Aroon Indicator for RPRX shows an upward move is likely

RPRX's Aroon Indicator triggered a bullish signal on November 12, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 268 similar instances where the Aroon Indicator showed a similar pattern. In 188 of the 268 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 70%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on RPRX as a result. In 51 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.

The Moving Average Convergence Divergence (MACD) for RPRX just turned positive on October 14, 2026. Looking at past instances where RPRX's MACD turned positive, the stock continued to rise in 34 of 50 cases over the following month. The odds of a continued upward trend are 68%.

RPRX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for RPRX crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 6 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 40%.

Following a +1.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where RPRX advanced for three days, in 174 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 15 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 21 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RPRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 49%.

RPRX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 17 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. RPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.386) is normal, around the industry mean (3.498). P/E Ratio (35.989) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (1.360) is also within normal values, averaging (9.059). Dividend Yield (0.014) settles around the average of (130.981) among similar stocks. P/S Ratio (12.870) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
REGN vs RPRX: Fundamental Ratings
REGN
RPRX
OUTLOOK RATING
1..100
4345
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
91
Overvalued
PROFIT vs RISK RATING
1..100
6217
SMR RATING
1..100
5997
PRICE GROWTH RATING
1..100
336
P/E GROWTH RATING
1..100
148
SEASONALITY SCORE
1..100
5015

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REGN's Valuation (88) in the Biotechnology industry is in the same range as RPRX (91) in the Pharmaceuticals Major industry. This means that REGN’s stock grew similarly to RPRX’s over the last 12 months.

RPRX's Profit vs Risk Rating (17) in the Pharmaceuticals Major industry is somewhat better than the same rating for REGN (62) in the Biotechnology industry. This means that RPRX’s stock grew somewhat faster than REGN’s over the last 12 months.

REGN's SMR Rating (59) in the Biotechnology industry is somewhat better than the same rating for RPRX (97) in the Pharmaceuticals Major industry. This means that REGN’s stock grew somewhat faster than RPRX’s over the last 12 months.

REGN's Price Growth Rating (3) in the Biotechnology industry is somewhat better than the same rating for RPRX (36) in the Pharmaceuticals Major industry. This means that REGN’s stock grew somewhat faster than RPRX’s over the last 12 months.

RPRX's P/E Growth Rating (8) in the Pharmaceuticals Major industry is in the same range as REGN (14) in the Biotechnology industry. This means that RPRX’s stock grew similarly to REGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
REGNRPRX
RSI
ODDS (%)
Bearish Trend 1 day ago
37%
Bearish Trend 1 day ago
52%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
66%
Bearish Trend 1 day ago
50%
Momentum
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 1 day ago
59%
MACD
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 1 day ago
68%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
64%
Bullish Trend 1 day ago
57%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
66%
Bullish Trend 1 day ago
60%
Advances
ODDS (%)
Bullish Trend 4 days ago
64%
Bullish Trend 2 days ago
56%
Declines
ODDS (%)
Bearish Trend 8 days ago
57%
Bearish Trend 10 days ago
49%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
51%
Bearish Trend 1 day ago
53%
Aroon
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 1 day ago
70%
COMPARISON
Comparison
Nov 13, 2026
Stock price -- (REGN: $959.41 vs. RPRX: $70.01)
Brand notoriety: REGN: Notable vs. RPRX: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: REGN: 139% vs. RPRX: 107%
Market capitalization -- REGN: $93.11B vs. RPRX: $29.97B
REGN [@Biotechnology] is valued at $93.11B. RPRX’s [@Biotechnology] market capitalization is $29.97B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

REGN’s FA Score shows that 2 FA rating(s) are green while RPRX’s FA Score has 2 green FA rating(s).

  • REGN’s FA Score: 2 green, 3 red.
  • RPRX’s FA Score: 2 green, 3 red.
According to our system of comparison, RPRX is a better buy in the long-term than REGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

REGN’s TA Score shows that 6 TA indicator(s) are bullish while RPRX’s TA Score has 6 bullish TA indicator(s).

  • REGN’s TA Score: 6 bullish, 4 bearish.
  • RPRX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both REGN and RPRX are a good buy in the short-term.

Price Growth

REGN (@Biotechnology) experienced а +3.09% price change this week, while RPRX (@Biotechnology) price change was +3.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.18%. For the same industry, the average monthly price growth was -2.37%, and the average quarterly price growth was -16.49%.

Reported Earning Dates

REGN is expected to report earnings on Jan 29, 2027.

RPRX is expected to report earnings on Feb 16, 2027.

Industries' Descriptions

@Biotechnology (+7.18% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

REGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, REGN has been loosely correlated with RPRX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then RPRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REGN
1D Price
Change %
REGN100%
-0.86%
RPRX - REGN
44%
Loosely correlated
-1.49%
VRTX - REGN
43%
Loosely correlated
-0.81%
EXEL - REGN
40%
Loosely correlated
-1.22%
INCY - REGN
39%
Loosely correlated
-0.47%
BMRN - REGN
36%
Loosely correlated
-2.79%
More

RPRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RPRX has been loosely correlated with VRTX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if RPRX jumps, then VRTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RPRX
1D Price
Change %
RPRX100%
-1.49%
VRTX - RPRX
49%
Loosely correlated
-0.81%
INCY - RPRX
49%
Loosely correlated
-0.47%
AXON - RPRX
48%
Loosely correlated
-2.63%
REGN - RPRX
41%
Loosely correlated
-0.86%
EXEL - RPRX
36%
Loosely correlated
-1.22%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WST411.30-1.56
-0.38%
West Pharmaceutical Services
VREX18.27-0.12
-0.65%
Varex Imaging Corp
ZGN13.57-0.46
-3.28%
Ermenegildo Zegna NV
MINE2.28-0.11
-4.60%
Mayfair Gold Corp
CABR0.80-0.06
-6.57%
Caring Brands Inc